Loading clinical trials...
Loading clinical trials...
Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
University Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt
Start Date
August 3, 2021
Primary Completion Date
November 28, 2021
Completion Date
December 12, 2021
Last Updated
January 19, 2023
128
ACTUAL participants
Colistin
DRUG
Lead Sponsor
Beni-Suef University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions